• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    compositions, system and method for nutritional intervention. it is a composition that includes a composition, a second composition and a third composition. the first composition comprises edible ingredients of fruit, seeds or parts of plants; the second composition comprises bitter gourd, a first oligosaccharide, a first fermentable dietary fiber or a combination thereof; and the third composition comprises a second oligosaccharide and a second fermentable dietary fiber. the composition is used to target and store the structural balance of intestinal microbiota and relieve chronic inflammation.
    公开号:BR112015011843B1
    申请号:R112015011843-7
    申请日:2013-11-26
    公开日:2021-04-06
    发明作者:Liping Zhao
    申请人:Shanghai Jiao Tong University；Perfect (China) Co., Ltd；
    IPC主号:
    专利说明:

    [0001] [001] This application relates to compositions to promote health. More specifically, the application provides compositions to promote beneficial intestinal microbiota or to inhibit opportunistic pathogens, as well as the preparation and use of the composition. BACKGROUND
    [0002] [002] Unless otherwise indicated in this document, the materials described in that section are not prior art to the claims in this application and are not admitted as prior art by inclusion in that section. All references are incorporated into this document in its entirety.
    [0003] [003] The metabolic syndrome is characterized, among others, by hyperglycemia, hypertension, high cholesterol and excess weight. Its most important factors are central obesity and insulin resistance. Metabolic syndrome is a predisposing high risk factor for many chronic diseases, such as diabetes, cardiovascular disease, cerebral apoplexy and colorectal cancer, making the metabolic syndrome one of the greatest health threats. The development of new technologies and methods to treat metabolic syndrome is of vital importance for public health.
    [0004] [004] Currently, the control of metabolic syndrome occurs mainly through the use of drugs and changing the composition of the diet. For a long time, due to the fact that there has been no progress in understanding the causes of the metabolic syndrome, the use of drugs has been limited to deal with the symptoms rather than the cause of the metabolic syndrome. Although symptoms can be relieved, disease processes are not blocked and most patients still develop different chronic illnesses. Attempts to deal with the metabolic syndrome by changing the composition of the diet do not perform well, due to the fact that previous efforts generally emphasize the function of a particular nutrient, while ignoring the underlying cause of metabolic syndrome. For example, several iterations of low-sugar food, to control blood sugar or low-fat food, to control blood lipids, are a popular protection, yet success is not common, improvement is limited due to the fact that the underlying cause of the metabolic syndrome is not properly dealt with. If the diet composition is substantially changed, for example, when switching from a high-calorie food of animal origin to a plant-based food or during the drastic reduction in calorie intake, patients tend to experience various adverse reactions, such as an unbearable desire for food or an increased level of inflammatory response, resulting in failure to strictly follow long-term medical advice. SHORT DESCRIPTION
    [0005] [005] The following summary description is illustrative only and is not intended to be in any way limiting. In addition to the illustrative aspects, achievements and resources described above, the additional aspects, achievements and resources will be apparent through reference to the drawings and detailed description below.
    [0006] [006] The present application refers to an unexpected revelation that the new composition is effective in promoting a beneficial intestinal bacterium while inhibiting opportunistic pathogens, resulting in the prevention and / or treatment of metabolic syndrome.
    [0007] [007] In one aspect, the application provides compositions to enhance the intestinal microbiota population. In one embodiment, the composition includes a first composition, a second composition and a third composition. The first composition can include an ingredient from an edible plant. The second composition may include bitter gourd, a first fermentable fiber and a first oligosaccharide; and the third composition can include a second fermentable dietary fiber and a second oligosaccharide. The first and second fermentable dietary fibers may or may not be the same. The first and second oligosaccharides may or may not be the same.
    [0008] [008] The ingredients in the compositions listed above may include seeds, fruits or other parts of their extracts from a plant that is edible and known or recognized for having medicinal or therapeutic activities.
    [0009] [009] When ingested by an individual in an effective amount, the composition may be able to increase a first intestinal microbiota population that includes the population of a bacterium that produces short chain fatty acid (SCFA), to decrease a second microbiota population intestinal which includes a bacterium that produces endotoxin in the individual, either to increase or decrease. For example, the first composition may be able to increase the first intestinal microbiota population and the second composition may be able to decrease the second intestinal microbiota population in the individual.
    [0010] [010] The compositions in this application can be food, nutraceutical products, supplements or health care products. The composition can be administered orally to an individual in need thereof. The individual can be a human being. The individual may suffer from metabolic syndrome.
    [0011] [011] In another aspect, the present application provides methods for producing the above compositions. In one embodiment, the method includes mixing capiá (adlay), oats, buckwheat, white beans, yellow corn, red beans, soybeans, yams, large jujubes, peanuts, lotus seeds and goji (wolfberry) to provide a first composition; mixing socaocaetano melon, a first fermentable dietary fiber and a first oligosaccharide to provide a second composition; and mixing a second fermentable dietary fiber and a second oligosaccharide to provide a third composition.
    [0012] [012] In a third aspect, the application provides methods for balancing intestinal microbiota and / or for improving metabolic syndrome in an individual. In one embodiment, the method includes the steps of administering to the individual an effective amount of a treatment composition. The treatment composition can include the first composition described above, the second composition described above, the third composition described above, or any combination of the three compositions.
    [0013] [013] Compared to existing techniques, the solutions in this application have, among others, one or more of the following surprising advantages: when administered to an individual, the compositions are capable of balancing or improving an individual's intestinal microbiota, improving syndrome metabolic, improve the amount of bacteria that produces short-chain fatty acid and decrease the amount of bacteria that produces endotoxin; the compositions can be administered to an individual in a number of ways and can moderate, alleviate, remedy, prevent or alleviate metabolic syndrome or symptoms of metabolic syndrome and / or restore an individual's health. BRIEF DESCRIPTION OF THE FIGURES
    [0014] [014] The above and other resources of this disclosure will be more fully apparent from the following description and claims, taken in combination with the accompanying drawings. Understanding that these drawings portray several achievements arranged only in accordance with the disclosure and, therefore, should not be considered as limiting the present scope, the disclosure will be described with specificity and additional details through the use of the attached drawings which: Figure 1 shows the VGE DGS 16S rRNA gene marks from the volunteers' intestinal microbiota population before and after the intervention. DETAILED DESCRIPTION
    [0015] [015] In the following detailed description, reference is made to the attached drawings, which form a part of this document. In the drawings, similar symbols identify similar components, unless the context indicates otherwise. The illustrative embodiments described in the detailed description, drawings and claims are not intended to be limiting. Other achievements can be used, and other changes can be made, without departing from the spirit and scope of the matter presented in this document. It will be readily understood that aspects of the present invention, as generally described in the present document and illustrated in the Figures, can be arranged, replaced, combined, separated and designated in a wide variety of different configurations, which are explicitly contemplated in the present document.
    [0016] [016] In one aspect, the application provides innovative compositions that are effective in promoting the beneficial intestinal microbiota population or inhibiting opportunistic pathogens. The composition can be a nutritional intervention composition. The composition can be made from common food ingredients and may not contain any artificial synthetic colors, hormones, sweeteners, flavoring agents, preservatives or any illicit drugs, so it is safe and non-toxic. The composition overcomes the insufficiency of existing nutritional intervention methods to treat metabolic syndrome and is effective in inhibiting intestinal opportunistic pathogens, in increasing the number of beneficial bacteria, in reducing chronic inflammation, thereby fundamentally improving the symptoms of metabolic syndrome.
    [0017] [017] In one embodiment, the composition includes a first composition, a second composition and a third composition. In one embodiment, the first composition comprises an ingredient from an edible plant. The second composition may contain São Caetano melon, a first fermentable dietary fiber and a first oligosaccharide; and the third composition contains a second fermentable dietary fiber and a second oligosaccharide.
    [0018] [018] The first composition may be able to increase the population of bacteria that produces short-chain fatty acid (SCFA) in an individual. In one embodiment, the first composition may include whole grains, beans, nuts, peanuts, maize (including, for example, yellow maize, white maize, red maize, purple maize, black maize, bicolor maize, multicolor maize), cloves India, anise star, fennel, thistle, yam, hawthorn, purslane, Zaocys dhumnades, plum, papaya, hemp seed, odoratum, fragrant Solomon Seal rhizome, licorice, angelica, ginkgo, lentils white, white lentil flower, longan pulp (also called Gui Yuan), cassia, lily, nutmeg, cinnamon, amla, bergamot, almond (both sweet and bitter), Hippophae rhamnoides, oysters, Gorgon fruit, pepper, red beans , donkey hide gelatin, interior wall of chicken gizzard, malt, seaweed ash, jujube (including, for example, Ziziphus jujube, sour jujube, or black jujube), Momordica grosvenori, Yu Li seed, lonicera flower, olive, Houttuynia cordata, ginger (including, for example, Zingiber officinale , fresh or dried), Hovenia dulcis Thunb, loquat, gardenia, Amomum villosum, Pang Dahai, Poria, cider, Elsholtzia, peach kernel, blackberry leaf, blackberry, orange, bell flower, Alpinia oxyphylla, lotus leaf, Semen Raphani, lotus seed, Alpinia officinarum hance, Lophatherum gracile, fermented soybeans, chrysanthemum, chicory, Huang Jiezi, Huang Jing, perilla seed, perilla seed, Ge Gen, black sesame seed, black pepper, Japanfork , sage flower, dandelion, honey, Torreya, semen Ziziphi Spinosae, Rhizoma imperatae, cane rhizome, viper, orange peel, capia (also known as coix seed or Yi Ren), mint, Allium macrostemon Bunge , raspberry, ageratum, or any combination thereof.
    [0019] [019] Beans can include soybeans, black beans, fava beans, common beans, peas, mung beans, whip beans, pigeon pea, winged beans, chickpeas, lentils, red beans, beans from the Rio de Janeiro group, green beans, purple beans, white beans, pea beans, lima beans, black beans, gravel beans, black-eyed beans, lablabe beans or any combination thereof. In one embodiment, lablabe beans may include common Hyacinth beans and white Hyacinth flowers. In one embodiment, lablabe beans can include beans from a Hyacinthus plant.
    [0020] [020] Nuts can include peach, almond, ginkgo seeds, or a combination thereof. In one embodiment, the almond may include a sweet almond or a bitter almond.
    [0021] [021] Whole cereals may include rice, wheat, barley, quinoa, rye, triticale, buckwheat or oats. Buckwheat may include common buckwheat, bitter tartar buckwheat, or a combination thereof. In one embodiment, buckwheat may include seeds from a Gagopyrum, Erigonum or Fallopia plant. Oats can include seeds from an Avena plant.
    [0022] [022] In one embodiment, the first composition may include powder or granular particles of whole cereals. In one embodiment, from about 15 to about 100% of the granular particles of whole cereal have a diameter of 0.65 mm or more. In some embodiments, at least about 15%, at least about 20%, at least about 25%, at least about 30% or at least about 50% of the granular particles of whole cereals have a diameter of 0.65 mm or more.
    [0023] [023] In one embodiment, the first composition may include buckwheat, oats, capia, or a combination of two, three, four, five, or six ingredients selected from the group. In another embodiment, the first composition may include oats, common Hyacinth beans, capiá or a combination of two, three, four, five or six ingredients selected from the group. In another embodiment, the first composition includes buckwheat, oats, yams or any combination of two, three, four, five or six ingredients selected from the group. For example, the first composition includes from about 10 to about 30% capia by weight, from about 5 to about 30% oats by weight, from about 5 to about 50% buckwheat by weight, from about 5 to about 20% common Hyacinth beans by weight, from about 5 to about 30% yam by weight, or any combination thereof. In one embodiment, the yam is dry yam.
    [0024] [024] In one embodiment, the first composition may include capiá, oats, buckwheat, common beans, yellow corn, red beans, soybeans, yams, peanuts, lotus seeds and goji. For example, the first composition includes about 20% by weight of capia, about 15% by weight of oats, about 10% by weight of buckwheat, about 10% by weight of common Hyacinth beans, about 5 % by weight of yellow corn, about 5% by weight of red beans, about 5% by weight of soy, about 10% by weight of dried yam, about 5% by weight of large jujube, about 5% by weight of peanuts, about 5% by weight of lotus seed, and about 5% by weight of goji.
    [0025] [025] In one embodiment, the first composition may include capiá, oats, buckwheat, lablabe beans, yellow corn, red beans, soy (or soy protein), yam, large jujube, peanuts, lotus seed, and goji. For example, the amount of capiá can be from about 10 to about 30%, for example, about 10%, about 15%, about 20%, about 25% or about 30%, by weight of the first composition. The amount of oats can be from about 5 to about 25%, for example, about 5%, about 10%, 15%, 20% or 25%, by weight of the first composition. Buckwheat can be from about 1 to about 20%, for example, about 1%, 5%, about 10%, about 15% or about 20%, by weight of the first composition. The amount of lablabe can be from about 1 to about 20%, for example, about 1%, about 5%, about 10%, about 15% or about 20%, by weight of first composition. The amount of the yam can be from about 1 to about 20%, for example, about 1%, about 5%, about 10%, about 15% or about 20%, by weight of the first composition. In some embodiments, the yams can be in dry, frozen, canned or extracted form. The amount of goji can be from about 5 to about 25%, for example, about 5%, about 10%, about 15%, about 20% or about 25%, of the first composition in weight. The amount of soybeans can be from about 1 to about 20%, for example, about 1%, about 5%, about 10%, about 15% or about 20%, of the first composition in weight.
    [0026] [026] In one embodiment, the amount of capiá, oats, buckwheat, common beans and yam in the first composition can be around 20%, about 15%, about 10%, about 10%, and 10% by weight, respectively, of the first composition, and the quantity of each yellow corn, red beans, soybeans, large jujube, peanuts, lotus seed, and goji can be situated at about 5% by weight of the first composition.
    [0027] [027] In one embodiment, the first composition can include, per 100 g, Vitamin A from about 3 to about 857 µgRE, Vitamin D from about 0.01 to about 5 µgRE, Vitamin E to from about 2 to about 79.09 mg, vitamin B1 from about 0.01 to about 1.89 mg, vitamin B2 from about 0.01 mg to about 1.4 mg, Vitamin B6 from about 0.01 to about 1.2 mg, Vitamin B12 from about 0.1 to about 2.4 mg, Vitamin C from about 1 mg to about 1,170 mg , Niacin from about 0.5 mg NE to about 28.4 mg, calcium (Ca) from about 60 to 2,458 mg, phosphorus (P) from about 200 to about 1,893 mg, potassium (K) from about 350 to about 1,796 mg, sodium (Na) from about 8 to about 2200 mg, magnesium (Mg) from about 100 to about 350 mg, and iron ( Fe) from about 2 to about 20mg.
    [0028] [028] In one embodiment, the first composition includes from about 5 to about 40% or from about 10 to about 20% protein by weight, from about 30 to about 80% or from about 50 to about 70% carbohydrate by weight, from about 0.5 to about 30% or from about 2 to about 15% fat by weight about 0.5 to about 30% or from about 2 to about 15% dietary fiber by weight, from about 0.1 to about 5% or from about 0.5 to about 1% Vitamin (s) by weight, or from about 0.1 to about 2% or from about 0.8 to about 1.2% mineral (s) by weight .
    [0029] [029] In one embodiment, each 100 grams of the first composition can provide a total from about 300 to about 400 calories. In one embodiment, the amount of protein, carbohydrate, fat, fiber, vitamin and mineral can be from about 13 to about 15%, from about 60 to about 65%, from about 4 to about 6%, from about 5 to about 7%, from about 0.5 to about 1%, and from about 0.8 to about 1.2% by weight, respectively, of the first composition.
    [0030] [030] The first composition can be in the form of rice, porridge, watery porridge, congee or cooked rice. The starch component in these forms is less likely to degrade after steam generation, boiling or other forms of cooking and is therefore less likely to raise the blood glucose level.
    [0031] [031] The second composition may be able to reduce the population of bacteria that produces endotoxin in an individual. In one embodiment, the second composition can consist essentially of melon-desão-caetano, the first fermentable fiber and the first oligosaccharides. The São Caetano melon can include powder of whole fruits of a plant of Momordica charantia or extracts of it. Fruit powder can be produced through a freeze-drying or spray drying process. The first fermentable dietary fiber may include Fibersol-2, resistant starch, polydextrose, cellulose, hemicellulose, pectin, gum, or a combination thereof. The first oligosaccharides can independently include fructo-oligosaccharides, galacto-oligosaccharides, lactulose, xyl isomalto-oligosaccharides, soy oligosaccharides, oligoglycosis, stachyose, lactosaccharose, or a combination thereof.
    [0032] [032] In one embodiment, the second composition can include from about 15 to about 99.8% of the caetano melon by weight, from about 0.1 to about 51% of the first fermentable dietary fiber by weight, and from about 0.1 to about 34% of the first oligosaccharide by weight. In one embodiment, the ratio of caetano melon and oligosaccharides in the second composition can be from about 10: 1 to about 1: 1 by weight. In one embodiment, the amount of São Caetano melon can be from about 15 to about 55%, for example, about 15%, about 20%, about 30%, about 35%, about 40%, about 45%, about 50% or about 55%, of the second composition by weight. In one embodiment, the amount of oligofructose can be from about 10 to about 30%, for example, about 10%, about 15%, about 20%, about 25% or about 30% , of the second composition by weight. In one embodiment, the amount of Isomalto-oligosaccharides can be from about 5 to about 25%, for example, about 5%, about 10%, about 15%, about 20% or about 25% of the second composition by weight.
    [0033] [033] The second composition can be in powder or granular form. For example, the second composition can be a granular infusion and can be dissolved or suspended in water. For example, the melon of sãocaocaetano can be in the form of powder.
    [0034] [034] The ingredients in the compositions can be in the form of powder, granules, particles, spaghetti, leaves, crystalline, paste or a solution. The ingredient powder, such as São Caetano melon, can be produced by freeze-drying or spray drying. In one embodiment, granular particles, spaghetti and leaves can be made by spraying a mixture of the ingredients into a particle or powdery mixture and forming the particle or powdery mixture into granular particles, spaghetti or leaves. In one embodiment, from at least about 1% to at least about 70% of the granular particles in the composition have a diameter of 0.65 mm or more.
    [0035] [035] The compositions in the present application can be used as food products, health care products or nutraceuticals, such as dietary supplements. When ingested by an individual in an effective amount, the composition may be able to increase a first population of intestinal microbiota that contains a bacterium that produces short chain fatty acid (SCFA), to decrease a second population of intestinal microbiota that contains bacteria that produces bacteria endotoxin in the individual, either to increase or decrease.
    [0036] [036] The composition can be mixed with a pharmaceutically acceptable carrier to form pharmaceutical compositions. "Pharmaceutically acceptable vehicles" include solvents, dispersants, coatings, sills, adhesives, bulking agents, biologically active agents, such as antibacterial or fungicidal agents, and isotonic and delayed absorption agents, which are suitable for drug delivery.
    [0037] [037] The composition can be formulated to be compatible with your intended route of administration. (See, for example, US Patent No. 6,756,196, which is incorporated by reference in its entirety by reference in its entirety.) Examples of routes of administration include oral, sublingual, mouth, and rectal administration, as well as parenteral administration. . For example, a composition of the present application can be in the form of a tablet, capsule, pill, bar, granule, powder, film, microcapsule, aerosol, watery porridge, congee, porridge, cooked rice or rice, spirit, tincture, tonic, suspension liquid or syrup. It is advantageous to formulate oral compositions in a unit dosage form to facilitate administration and uniformity of dosage. The "dosage unit form", as used in this document, refers to physically distinct units suitable as unitary units for the individual to be treated, each unit containing a predetermined amount of active ingredients calculated to produce the necessary therapeutic effect in association with the required pharmaceutical carrier.
    [0038] [038] The composition of the present application can be used to promote beneficial intestinal bacteria and to inhibit opportunistic pathogens. Therefore, the application provides systems for nutritional intervention to reduce body weight or to treat metabolic syndrome in an individual. The system can include the above compositions and an instruction set up to instruct the individual on how to use the first composition, the second composition, and the third composition.
    [0039] [039] For example, an effective amount of the composition can be administered to an individual in need of it via an appropriate route, such as those described above.
    [0040] [040] As used herein, an "individual" refers to a human or an animal, including all mammals, such as, (particularly higher primates), sheep, dogs, rodents (for example, mice or rats) , guinea pigs, goat, pig, cat, rabbit and cow. In a preferred embodiment, the individual is a human. In another embodiment, the individual is an experimental animal or an animal suitable as a model of disease.
    [0041] [041] An individual to be treated can be identified in the judgment of the individual or a health professional, and can be subjective (eg, opinion) or objective (eg, measurable by a test or a diagnostic method). For example, an individual being treated may have a low level of beneficial intestinal bacteria and a high level of opportunistic pathogens, or has been diagnosed with metabolic syndrome.
    [0042] [042] A "treatment" is defined as the administration of a substance to an individual for the purpose of curing, moderating, relieving, remedying, preventing or alleviating a disorder, symptoms of the disorder, a disease state secondary to the disorder or a predisposition to the disorder.
    [0043] [043] An "effective amount" is an amount of a composition capable of producing a medically desirable result in a treated individual. The medically desirable result can be objective (that is, measurable by some test or marker) or subjective (that is, the individual generates an indication of an effect or appears to be an effect).
    [0044] [044] The dosage required to treat an individual depends on the choice of route of administration, the nature of the formulation, the nature of the individual's illness, the size of the individual, weight, surface area, age, gender, other drugs that administered and / or the judgment of a health professional.
    [0045] [045] The application additionally provides instructions for taking the above compositions. In one embodiment, the individual is instructed to take the first composition as a main course of food, to take the second composition from about 0.25 to about 1 hour before the meal, and to take the third composition from about from 2 to about 5 hours before the meal or with breakfast.
    [0046] [046] In one embodiment, the first composition can be in the form of porridge, watery porridge or congee and can be used as food by an individual, optionally in combination with fresh vegetables. The amount of ingestion of the first composition can be adjusted to the point that the individual no longer feels hungry. The second composition can be in the form of a granular infusion. The granular infusion can be suspended or dissolved in warm water and consumed by an individual. The daily intake amount of the second composition can be from about 5 to about 100 grams, from about 30 to about 80 grams, or from about 40 to about 60 grams. For example, the individual may be instructed to take 2 to 3 bags at a dosage of 20g / bag per day for the second composition with warm water. The third composition can also be a granular infusion. The daily intake amount of the third composition can be from about 5 to about 200 grams, from about 30 to about 100 grams or from about 50 to about 150 grams. The third composition can be suspended or dissolved in about 300 to about 1500 ml or from about 800 to about 1200 ml of water and then consumed by an individual on an empty stomach in the morning.
    [0047] [047] The administration cycle representative of the composition of this application starts from one week to several months, for example, one week, two weeks, one month, two months, four months or eight months. When the level of beneficial intestinal microbiota in the individual's body begins to rise and the level of opportunistic pathogens begins to decline, the dosage of the composition may be reduced gradually. When the composition of the intestinal microbiota is restored to normal, administration can be terminated.
    [0048] [048] The following examples are for purposes of illustrating the present application. The achievements were implemented based on the premise of the technical solution of this application. Detailed deployment methods and specific operating processes are provided. These examples are not intended to limit the scope of the order. EXAMPLE 1 EFFECTIVE TREATMENT OF AN OBESE VOLUNTEER FOR AN EXEMPLIFICATIVE COMPOSITION
    [0049] [049] The composition incorporating the present application in a granular infusion form was administered to a volunteer with a Body Mass Index (BMI) of 58.78 daily for 24 weeks. The physiological and biochemical indicators of the body and changes in the intestinal microbiota during administration were systematically monitored. At the end of the intervention, opportunistic pathogens in the intestine declined; the beneficial bacteria in the gut has increased; intestinal endotoxins entering the host's circulatory system have been reduced, the level of inflammatory response in the volunteer has been lowered; each and every parameter of the volunteer's metabolic syndrome has been significantly improved; and the BMI declined to 41.50. (1) THE PHYSICAL CONDITIONS OF THE VOLUNTEER BEFORE THE INTERVENTION
    [0050] [050] The volunteer was a 26-year-old male, with height of 172.5 cm, weight of 174.9 kg, BMI of 58.78 and waist of 156.1 cm. According to BMI assessment criteria for Asian adults, this volunteer was a severely obese patient. After a systematic physical examination, this volunteer was diagnosed with severe metabolic syndrome. Its physiological and biochemical indicators are shown in Table 1 below. (2) THE COMPOSITION USED FOR PATIENT INTERVENTION AND TREATMENT
    [0051] [051] For the intervention and treatment of the patient, a granular infusion form of an exemplary composition was used. The exemplary composition has the following formula: the amount of São Caetano melon powder was 35%, the amount of goji powder was 15%, the amount of soy protein powder was 10%, the amount of oligofructose was 20%, the amount of Isomalto-oligosaccharides was 15%, and the amount of wheat fiber was 5%. This composition has good inhibitory effects for intestinal opportunistic pathogens and was able to specifically condition the contents of the intestinal flora, as demonstrated by the results obtained.
    [0052] [052] The granular infusion was taken orally in 2 to 3 bags per day (20g / bag), after dissolving in warm water. (3) USE OF OTHER INTERVENTION FOOD A. Composition Similar to Food No. 1. Composition Similar to Food No. 1 is an exemplary composition in the form of porridge. The composition has the ingredients including capiá, oats, buckwheat, common beans, yellow corn, red beans, soy, yams, large jujube, peanuts, lotus seed and goji. This food-like composition was an integral product, with balanced protein, carbohydrates and fat. Rich in dietary fiber. With the capacity to supplement the dietary and nutritional needs of the human body, such as vitamins and minerals.
    [0053] [053] The patient consumed Food Composition No. 1 as a food base along with an adequate amount of fresh vegetables during each meal. Food intake was not restricted and the patient was able to consume the food at will until he was no longer hungry. B. Food-like composition No. 3: Food-like composition No. 3 is an exemplary composition in the form of granular infusion. The composition has ingredients that include the oligomeric factor and fermentable dietary fiber. This food-like composition can clean the intestinal tract, exclude feces, promote beneficial intestinal bacteria, increase gas production by the beneficial intestinal bacteria, accelerate motility and intestinal emptying, and remove pathogenic bacteria and bacteria that produces endotoxin.
    [0054] [054] This food-like composition contained 30 to 100 grams of oligosaccharides. The patient consumed this food-like composition every morning before another food, along with 800 to 1,200 ml of water. (4) EVALUATION OF CHANGES IN PHYSIOLOGICAL AND BIOCHEMICAL INDICATORS OF THE BODY AND EFFECTS OF INTERVENTION
    [0055] A. A intervenção pela composição do presente pedido reduziu significativamente o BMI e aprimorou drasticamente a síndrome metabólica. Em comparação aos indicadores fisiológicos e bioquímicos do voluntário, 0 dia antes da intervenção, após 9 semanas e 23 semanas de intervenção, o peso e o BMI do voluntário decaíram significativamente; a diminuição dos indicadores de glicose em jejum, de insulina em jejum, de hemoglobina glicosilada e de resistência à insulina reflete diretamente o aprimoramento significativo do estado de homeostase de glicose sob a intervenção; o declínio total de triglicerídeos e de colesterol indica o aprimoramento do metabolismo de lipídio do corpo; a redução significativa e o retorno gradual à faixa normal de aspartato aminotransferase, de alanina aminotransferase e de γ-glutamiltransferase indica a mitigação do dano às células hepáticas; ao mesmo tempo, tanto os sintomas de doença hepática gordurosa quanto a pressão sanguínea foram aliviados; a diminuição tanto do indicador inflamatório proteína reativa C quanto do fator inflamatório interleucina-6 sugere que o nível da resposta inflamatória causada pela população de microbiota intestinal e que tem um efeito destrutivo no corpo humano foi reduzido sob a intervenção; o aumento do fator anti-inflamatório adiponectina indica que a função do corpo para eliminar resposta inflamatória se recuperou após a intervenção; a diminuição da proteína de ligação de endotoxina de lipopolissacarídeo sugere que o nível da endotoxina produzida pela bactéria e que entra no sangue foi reduzido sob a intervenção. Considerados juntamente, todos esses indicadores mostram que, após a intervenção no voluntário, cada parâmetro da síndrome metabólica do voluntário foi aprimorado significativamente. B. A intervenção pela composição do presente pedido mudou significativamente a composição da flora intestinal, aumentando a bactéria benéfica e diminuindo bactéria nociva. As mudanças da composição da microbiota intestinal durante a intervenção foram medidas pela marca do gene 16S rRNA de DGGE de V3. Conforme mostrado na Figura 1, a marca do gene 16S rRNA de DGGE de V3 mostra que a intervenção dietética exerceu um grande impacto na composição da microbiota intestinal nesse indivíduo. Em diversos pontos, após a intervenção, a microbiota intestinal do voluntário foi relativamente semelhante, indicando que a intervenção dietética mudou significativamente a composição da flora intestinal. C. Os resultados de pirossequenciamento 454 revelam uma diminuição significativa em Proteobactéria no voluntário. Em particular, a mudança em Enterobacteriaceae foi mais proeminente, a partir de 17,90% em -30d a 0,10% em 9 semanas e 0,10% em 23 semanas. Com reflexão no nível de gênero, manifestou-se pelo declínio significativo do patógeno oportunista Enterobacter. Além disso, no nível de gênero, após a intervenção dietética, a Faecalibacterium se elevou. A Faecalibacterium é anti-inflamatória e produz butirato. A mesma exerce uma função importante no metabolismo de energia em um hospedeiro e a proteção da integridade da mucosa intestinal. [055] TABLE 1 shows the physiological and biochemical indicators of the volunteer in example 1 after 9 weeks and 23 weeks of intervention
    [0056] [056] Thus, after the intervention, the number of opportunistic pathogens in the volunteer declined. Intestinal endotoxins entering the host's circulatory system have been reduced, the level of inflammatory response in the host has been lowered and the symptoms of metabolic syndrome in the volunteer have been effectively relieved EXAMPLE 2 EFFECTIVE TREATMENT OF 89 OBESE VOLUNTEERS FOR AN EXEMPLIFICATIVE COMPOSITION
    [0057] [057] The same exemplary composition and intervention regime, as described in EXAMPLE 1, were applied to 89 volunteers who suffered from second-degree central obesity. Physiological and biochemical indicators and changes in the intestinal microbiota during intervention were systematically monitored for all 89 volunteers. After administering the composition in a granular infusion form daily for 24 weeks, opportunistic pathogens in the intestine declined; the beneficial bacteria in the gut has increased; intestinal endotoxins entering the host's circulatory system have been reduced, the level of inflammatory response in the volunteer has been significantly lowered; each and every parameter of the volunteer's metabolic syndrome has been significantly improved; and the BMI has been reduced significantly. (1) THE VOLUNTEER'S PHYSICAL CONDITIONS BEFORE THE INTERVENTION.
    [0058] [058] 89 volunteers suffering from second-degree central obesity were recruited for the application. (2) THE COMPOSITION USED FOR THE INTERVENTION AND TREATMENT OF THE PATIENT.
    [0059] [059] The same composition as in EXAMPLE 1 was used. (3) THE USE OF ANOTHER COMPOSITION LIKE INTERVENTION FOOD.
    [0060] [060] The same composition as in EXAMPLE 1 was used. (4) THE EVALUATION OF CHANGES IN THE BODY'S PHYSIOLOGICAL AND BIOCHEMICAL INDICATORS AND THE EFFECTS OF INTERVENTION.
    [0061] [061] The data shown in TABLE 2 below are the mean value ± standard deviation or median (interquartile distance). The paired t-test (normally distributed data) or the non-parametric Wilcoxon test distribution (data not normally distributed) were analyzed using SPSS 17.0 statistical software. For comparison between week 9 versus -30 days, and week 23 versus -30 days, * denotes P ˂0.05, ** denotes P ˂0.01; for comparison between week 9 versus week 23, § denotes P ˂0.05, § § denotes P ˂0.01.
    [0062] A. Em comparação aos indicadores fisiológicos e bioquímicos dos voluntários 30 dias antes da intervenção, 9 semanas e 23 semanas após a intervenção, o peso do corpo e o BMI dos voluntários de decaíram de maneira significativamente contínua; a diminuição nos indicadores de glicose em jejum, de insulina em jejum, de hemoglobina glicosilada, e de resistência à insulina reflete diretamente no aprimoramento de homeostase de glicose sob a intervenção; o declínio em triglicerídeos e no colesterol total indica o aprimoramento do metabolismo de lipídio do corpo; a redução significativa de aspartato aminotransferase, de alanina aminotransferase e de γglutamiltransferase indica a mitigação do dano às células hepáticas; ao mesmo tempo, tanto a doença hepática gordurosa (68,5% das condições voluntários aprimoraram-se sob a intervenção, dentre a qual 18,0% retornou ao normal) quanto a pressão sanguínea foram aliviadas; a diminuição tanto do indicador inflamatório proteína reativa C quanto dos fatores inflamatórios Interleucina-6 e o fator de necrose tumoral -α sugere que o nível da resposta inflamatória causada pela microbiota intestinal foi reduzido sob a intervenção; o aumento do fator anti-inflamatório adiponectina indica que a função do corpo elimina resposta inflamatória recuperada após a intervenção; a diminuição da proteína de ligação de endotoxina de lipopolissacarídeo sugere que o nível da endotoxina produzida pela bactéria e que entra no sangue foi reduzido sob a intervenção. B. A intervenção pela composição do presente pedido mudou significativamente a composição da flora intestinal. Os resultados de pirossequenciamento 454 mostram que o número de Proteobactéria nos voluntários diminuiu significativamente ao mesmo tempo em que o número de Actinomicetos aumentou significativamente após a intervenção. Primeiramente, três famílias mostraram óbvias mudanças após a intervenção dietética. Os números de Enterobacteriaceae e de Desulfovibrio decaíram significativamente, ao mesmo tempo em que o número de Bifidobactéria aumentou significativamente. [062] Note: For the intestinal permeability test, 89 samples were collected 30 days before the intervention and 9 weeks after the intervention. 76 samples were collected 23 weeks after the intervention. A. In comparison to the volunteers 'physiological and biochemical indicators 30 days before the intervention, 9 weeks and 23 weeks after the intervention, the volunteers' body weight and BMI declined significantly continuously; the decrease in fasting glucose, fasting insulin, glycosylated hemoglobin, and insulin resistance indicators directly reflects the improvement of glucose homeostasis under intervention; the decline in triglycerides and total cholesterol indicates an improvement in the body's lipid metabolism; the significant reduction in aspartate aminotransferase, alanine aminotransferase and γglutamyltransferase indicates the mitigation of damage to liver cells; at the same time, both fatty liver disease (68.5% of voluntary conditions improved under the intervention, 18.0% of which returned to normal) and blood pressure were alleviated; the decrease in both the inflammatory indicator C-reactive protein and the inflammatory factors Interleukin-6 and the tumor necrosis factor -α suggests that the level of the inflammatory response caused by the intestinal microbiota was reduced under the intervention; the increase in the anti-inflammatory factor adiponectin indicates that the body's function eliminates the inflammatory response recovered after the intervention; the decrease in the lipopolysaccharide endotoxin-binding protein suggests that the level of the endotoxin produced by the bacteria and entering the blood has been reduced under intervention. B. The intervention for the composition of the present application significantly changed the composition of the intestinal flora. The results of pyrosequencing 454 show that the number of Proteobacteria in the volunteers decreased significantly at the same time that the number of Actinomycetes increased significantly after the intervention. First, three families showed obvious changes after the dietary intervention. The numbers of Enterobacteriaceae and Desulfovibrio declined significantly, while the number of Bifidobacteria increased significantly.
    [0063] [063] After the intervention, the numbers of two types of common pathogens, Enterobacteriaceae and Desulfovibrio, in the volunteers declined significantly, while the number of Bifidobacteria, which can protect the intestinal barrier, increased significantly. Intestinal permeability has been lowered and the intestinal endotoxins entering the circulatory system of the host have been reduced, resulting in a decrease in the level of inflammatory response in the host and in the relief of symptoms of metabolic syndrome.
    [0064] [064] From the above, it will be noted that, although specific realizations of the order have been described in this document for purposes of illustration, various modifications can be made without departing from the spirit and scope of the order. Consequently, the claim is limited to the appended claims only.
    [0065] [065] In relation to the use of any plural and / or singular terms in this document, persons skilled in the art may translate from the plural to the singular and / or from the singular to the plural, as appropriate to the context and / or the app. The various permutations of singular / plural can be presented expressly in this document for the purpose of clarification.
    [0066] [066] Persons skilled in the art will understand that, in general, the terms used in this document, and especially in the appended claims (for example, bodies of the appended claims) are generally intended to be “open” terms (for example , the term “including” should be interpreted as “including, but without limitation”, the term “that has” should be interpreted as “that has at least”, the term “includes” should be interpreted as “includes, but without limitation ", etc.). People skilled in the art will further understand that if a specific number of an introduced claim recital is intended, that intention will be recited explicitly in the claim and, in the absence of that recitation, that intention is not present. For example, as an aid to understanding, the following appended claims may contain the use of the introductory phrases "at least one" and "one (or more) to introduce claim claims. However, the use of such phrases should not be interpreted as implying that the introduction of a claim claim by the indefinite articles "one" or "one" limits any particular claim that contains such claim claim introduced to accomplishments that contain only one recitation. , even when the same claim includes the introductory phrases "one (or more) or" at least one (a) "and indefinite articles, such as," one "or" one "(e.g.," one "and / or “one” should be interpreted as “at least one (a)” or “one (a) or more”); the same holds true for the use of defined articles used to introduce claim claims. Furthermore, even if a specific number of an introduced claim recitation is recited explicitly, persons skilled in the art will recognize that such recitation should not be interpreted as just the recited number (for example, the mere recitation of “two recitations”, without other modifiers, means at least two recitations or two or more recitations).
    [0067] [067] In addition, in instances where a convention analogous to “at least one (a) out of A, B, and C, etc.” in general, such a construction is used in the sense that a person skilled in the art understands the convention (for example, “a system that at least one of (a) out of A, B, and C” includes, but is limited to, systems that have only A, only B, only C, A and B together, A and C together, B and C together and / or A, B, and C together, etc.). People skilled in the art will additionally understand that virtually any word and / or phrase that has two or more alternative terms, if present in the description, claims or drawings, should be understood as contemplating the possibilities that include one among the terms, each of the terms or both terms. For example, the phrase "A or B" will be understood as including the possibilities of "A" or "B" or "A and B."
    [0068] [068] In addition, when the resources or aspects of the disclosure are described in terms of Markush groups, people skilled in the art will recognize that the disclosure is thus also described in terms of any individual member or subgroup of group members Markush. As will be understood by a person skilled in the art, for any and all purposes, for example, in terms of providing a written description, all of the ranges disclosed in this document also cover any and all possible sub-ranges and combinations of sub-ranges of the same. Any track listed can easily be recognized as sufficiently descriptive and enabling the same track that is broken into at least two, three, four, five, ten equal parts, etc. As a non-limiting example, each track discussed in this document can be readily broken into a third lower part, a third intermediate part and a third upper part, etc. As will also be understood by a person versed in the technique all language, such as, "up to", "at least", "greater than", "less than" and the like, includes the recited number and refers to the tracks that can subsequently started in sub-bands, as discussed above. Finally, as a person skilled in the art will understand, a banner includes each individual member. For example, a group that has 1 to 3 cells refers to groups that have 1, 2, or 3 cells. Similarly, a group that has 1 to 5 cells refers to groups that have 1, 2, 3, 4, or 5 cells, and so on. Although various aspects and achievements have been revealed in this document, other aspects and achievements will be apparent to those skilled in the art.
    [0069] [069] The various aspects and achievements disclosed in this document are for purposes of illustration and are not intended to be limiting, the true spirit and scope of the invention being indicated by the following claims.
    权利要求:
    Claims (6)
    [0001]
    COMPOSITION TO PROMOTE INTESTINAL HEALTH, more precisely a combined composition, characterized by comprising a first composition, a second composition and a third composition, to improve a metabolic syndrome in an individual, where the first composition comprises capiá (adlay), oats, buckwheat, white beans, yellow corn, red beans, soybeans, yams, large jujubes, peanuts, lotus seeds and goji (wolfberry); wherein the second composition comprises from 15 to 99.8% by weight of São Caetano melon, from 0.1 to 51% by weight of a first fermentable dietary fiber and from 0.1 to 34% by weight of a first oligosaccharide; wherein the third composition comprises a second fermentable dietary fiber and a second oligosaccharide.
    [0002]
    COMPOSITION, according to claim 1, characterized by (i) the São Caetano melon comprises powder or whole fruits of a Momordica plant, or (ii) the São Caetano melon comprises extracts or whole fruits from a Momordica plant, or (iii) the first or second fermentable dietary fiber independently comprises resistant starch, polydextrose, cellulose, hemicellulose, pectin, gum or a combination thereof, or (iv) the first or the second oligosaccharide independently comprises fructo-oligosaccharides, galacto-oligosaccharides, lactulose, xylisomalto-oligosaccharides, soy oligosaccharides, oligoglucose, stachyose, lactosaccharose or a combination thereof.
    [0003]
    COMPOSITION, according to claim 2, characterized by: (i) buckwheat comprises common buckwheat, bitter tartar wheat or a combination thereof; or (ii) buckwheat comprises seeds from a Gagopyrum, Erigonum or Fallopia plant; or (iii) oats comprise seeds of an Avena plant.
    [0004]
    COMPOSITION, according to claim 1, characterized by the first composition comprising, for every 100g, vitamin A from 3 to 857 µgRE, vitamin D from 0.01 to 5 µgRE, vitamin E from 2 to 79.09 mg, vitamin B1 from 0.01 to 1.89 mg, vitamin B2 from 0.01 mg to 1.4 mg, vitamin B6 from 0.01 to 1.2 mg, vitamin B12 from 0.1 to 2.4 mg, vitamin C from 1 mg to 1170 mg, niacin from 0.5 mgNE to 28.4 mg, Cafrom 60 to 2458 mg, P from 200 to 1893 mg, K from 350 to 1796 mg, Na from 8 to 2200 mg, Mg from 100 to 350 mg and Fe from 2 to 20 mg.
    [0005]
    COMPOSITION according to claim 1, characterized in that the second composition is in the form of powder.
    [0006]
    COMPOSITION, according to claim 1, characterized in that the first composition comprises from 10 to 20% of protein by weight, from 2 to 15% of fat by weight, from 50 to 70% of carbohydrate by weight and from 2 to 15% of fermentable dietary fiber by weight.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112015011843B1|2021-04-06|COMPOSITION TO PROMOTE INTESTINAL HEALTH
    CN107183705A|2017-09-22|A kind of relax bowel improves the functional food of constipation
    JP2016172761A|2016-09-29|Composition for controlling intestinal disorder and/or improving bowel movement
    AU2009222618B2|2012-12-13|NGNA compositions and methods of use
    CN106135891A|2016-11-23|A kind of health food to alcoholic liver injury with defencive function
    US8394425B2|2013-03-12|Methods for promoting cellular health and treatment of cancer
    BR112020010843A2|2020-11-10|human milk oligosaccharides and synthetic compositions for modulation of the microbiota
    CN101243882B|2011-05-04|Health food with function of reducing blood fat and its preparation
    CN111317775A|2020-06-23|Application of preparation for removing food retention and relieving cough for children in preparation of medicine for treating fever and preparation method thereof
    CN104523925B|2017-05-24|Traditional Chinese medicinal composition and its application in defecation promotion
    CN109349618A|2019-02-19|Constipation tailored version clinical nutrition formula and preparation method thereof
    Bager et al.2012|Assessment report on Zingiber officinale Roscoe, rhizoma
    Sudheer et al.2021|Shaping the gut microbiota by bioactive phytochemicals: An emerging approach for the prevention and treatment of human diseases
    CN106349318B|2017-12-08|A kind of application of pentacyclic triterpene compound in obesity treating medicine is prepared
    WO2014154008A1|2014-10-02|Purgative composition, preparation method therefor and application thereof
    AU2015266075B2|2020-06-18|Oral composition for improving systemic symptoms including sensitivity to cold
    BR102020016156A2|2022-02-15|Regulatory composition of the neuro-immune-endocrine system
    CN107921058A|2018-04-17|Prevention effect of the synanthrin to nasosinusitis
    JP2022036990A|2022-03-08|Composition that promotes intestinal health
    CN106728620B|2020-09-11|Bowel relaxing mixture for improving constipation of tumor chemotherapy patients
    JP7011885B2|2022-01-27|Composition that promotes intestinal health
    WO2021222997A1|2021-11-11|Composition for regulating the neuro-immune-endocrine system
    Du et al.2020|Experimental study on acute toxicity of Lucao Wenban granules
    BR112014030570B1|2021-02-09|extracts of wild thyme and use of these
    CN113730519A|2021-12-03|Digestion promoting tablet and preparation method thereof
    同族专利:
    公开号 | 公开日
    RU2607351C1|2017-01-10|
    IL238549D0|2015-06-30|
    SA515360473B1|2018-11-08|
    MX364817B|2019-05-08|
    EP2925159A1|2015-10-07|
    AU2013351692B2|2017-04-06|
    BR112015011843A2|2017-07-11|
    WO2014082560A1|2014-06-05|
    CA2891922A1|2014-06-05|
    CN102987383B|2016-03-23|
    JP2016505533A|2016-02-25|
    IL238549A|2017-12-31|
    KR20150088263A|2015-07-31|
    US20150296851A1|2015-10-22|
    KR102301577B1|2021-09-13|
    BR112015011843B8|2021-05-18|
    ZA201503554B|2016-10-26|
    AU2013351692A1|2015-06-04|
    MX2015006514A|2015-11-16|
    MY173960A|2020-02-28|
    EP2925159A4|2016-06-22|
    SG11201503632PA|2015-06-29|
    JP6271571B2|2018-01-31|
    BR112015011843A8|2021-03-09|
    HK1210669A1|2016-05-06|
    CN102987383A|2013-03-27|
    EP2925159B1|2018-11-07|
    CA2891922C|2020-08-18|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    CN1084026A|1992-09-14|1994-03-23|贾文成|Preparation method with imperial court dinner congee of health care|
    AT308254T|1998-12-15|2005-11-15|Nestle Sa|BALANCE MIXTURE FOR ENTERAL COMPOSITION|
    EP1175905A1|2000-07-24|2002-01-30|Societe Des Produits Nestle S.A.|Nutritional Composition|
    DE60221234T2|2001-04-09|2008-05-21|Danisco A/S|USE OF FILLERS AS SATURATING AGENTS|
    GB2412834A|2004-04-07|2005-10-12|International Ltd Valid|A ready-to-use nutritional supplement|
    JP2006212025A|2005-01-07|2006-08-17|Amikku Group:Kk|Dried powdered food|
    CA2626398C|2005-10-24|2011-04-19|Nestec S.A.|Dietary fiber formulation and method of administration|
    WO2008115046A1|2007-03-22|2008-09-25|N.V. Nutricia|Cereal-based infant nutrition with fibre|
    CN101120757A|2007-09-10|2008-02-13|林鸿仿|Vegetarian meat five cereals food|
    CN101278736B|2008-03-28|2014-05-07|西安力邦制药有限公司|Balanced enteral total nutrient preparation suitable for nutrition support of Asian population|
    US20090252758A1|2008-04-07|2009-10-08|Mazed Mohammad A|Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance|
    CN101606692A|2008-06-19|2009-12-23|刘泳宏|A kind of natural colour viscera-nourishing nutritional porridge and preparation method|
    MX2011011659A|2009-05-07|2012-02-28|Tate & Lyle Ingredients France SAS|Compositions and methods for making alpha--branched alpha- oligodextrans.|
    JP2011020925A|2009-07-13|2011-02-03|Ikeda Shokken Kk|Offal fat-type overweight inhibitor and method for producing the same|
    WO2011020853A1|2009-08-18|2011-02-24|Cosucra-Groupe Warcoing Sa|Compositions containing mixtures of fermentable fibers|
    CN101658296A|2009-09-28|2010-03-03|牟思政|Life-prolonging nutritious gruel and preparing method|
    AU2010319490B2|2009-11-12|2015-03-19|Société des Produits Nestlé S.A.|Nutritional composition for promoting gut microbiota balance and health|
    CN102258167A|2010-05-27|2011-11-30|赵宪梅|Nourishing Chinese date porridge|
    CN102370165A|2010-08-11|2012-03-14|陈秋田|Nutritious breakfast food and preparation method thereof|
    CN102038184B|2010-09-10|2012-02-29|安徽燕之坊食品有限公司|Grain and fruit nut solid beverage and processing method thereof|
    EA038621B1|2010-10-14|2021-09-23|Аша Ньютришн Сайенсиз, Инк.|Optimized nutritional formulations, methods for selection of tailored diets therefrom, and methods of use thereof|
    US9463169B2|2011-08-17|2016-10-11|Microbiome Therapeutics, Llc|Human gastrointestinal microbiome modulating food supplement for improving blood glucose regulation|
    CN102273585B|2011-09-15|2013-03-20|杭州娃哈哈集团有限公司|Health-care porridge with effect of relaxing bowel and preparation method thereof|
    CN102743420A|2012-06-06|2012-10-24|上海交通大学|Method for improving intestinal colony structure and application|
    US20150296851A1|2012-11-27|2015-10-22|Shanghai Jiao Tong University|Compositions for Balancing Gut Microbiota and the Preparation and the Uses thereof|US20150296851A1|2012-11-27|2015-10-22|Shanghai Jiao Tong University|Compositions for Balancing Gut Microbiota and the Preparation and the Uses thereof|
    CN103462029B|2013-07-18|2015-04-22|浙江劲膳美生物科技有限公司|Special diet for people with spleen deficiency and weak qi|
    CN103355463A|2013-07-18|2013-10-23|安徽宜康食品有限公司|Lily coffee and preparation method thereof|
    WO2015010323A1|2013-07-26|2015-01-29|Yang Chenglin|Chinese herbal medicine additive for the prevention of swine fever|
    CN103478195B|2013-09-04|2014-07-09|焦新年|Health-maintenance horseshoe pancake|
    CN103876131A|2013-11-21|2014-06-25|桂平市科技企业创新服务中心|Nutrient weight losing composition and preparation method thereof|
    CN103550754B|2013-11-25|2015-10-07|三株福尔制药有限公司|A kind of probiotics fermention Traditional Chinese medicine compound composition for auxiliary hyperglycemic and its preparation method and application|
    CN103750104B|2014-01-16|2015-08-19|广东维美健健康食品有限公司|A kind ofly comprehensively improve health food of the uncomfortable disease of spleen and gastrointestinal tract and preparation method thereof|
    CN104041644B|2014-07-08|2016-05-11|胡伟斌|Bowel tea and preparation method thereof|
    CN104208275B|2014-08-29|2017-08-01|苏州雷允上健康养生有限公司|It is a kind of that there is improvement fatty liver, composition of losing weight effect and its preparation method and application|
    CN104189072B|2014-09-12|2018-01-12|兰州古驰生物科技有限公司|A kind of Chinese medicine preparation for being used to release vivotoxin|
    CN104473026A|2014-12-25|2015-04-01|周连平|Special nutrition powder for patients with hypertension and hyperlipidemia|
    KR101578070B1|2015-04-08|2015-12-16|김경일|Health supplementing food for enhancing hair restoration, alleviating and improving hair loss, adjusting blood sugar, alleviating and improving gastrointestinal disorders|
    CN104757549B|2015-04-23|2017-05-31|国药集团健康产业研究院有限公司|One kind relaxes bowel composition|
    CN104904930A|2015-05-05|2015-09-16|禹州市鼎信中药科技有限公司|Gardenia jasminoides and honeysuckle substitute tea and preparation method thereof|
    CN104905269A|2015-05-18|2015-09-16|合肥市好旺养殖科技有限公司|Tenebrio molitor nutritional medicinal liquid|
    CN104856035A|2015-06-03|2015-08-26|贵州广济堂药业有限公司|Health-care product for recuperating specific intrinsic constitution|
    CN106307032A|2015-06-29|2017-01-11|桂林洁宇环保科技有限责任公司|Chinese yam-corn health-care food capable of enhancing human body immunity and good in taste|
    CN106310006A|2015-06-30|2017-01-11|完美（中国）有限公司|Application of composition packet in preparing food, medicines, health care products and nutrition for improving and treating human Prader-Willi syndrome|
    CN105309993A|2015-10-20|2016-02-10|上海中优生物高科技有限责任公司|Application of whole grain and compositions thereof for controlling body weight regain|
    CN106237168B|2015-10-21|2020-09-08|完美（广东）日用品有限公司|Application of combined bag in preparation of food, medicine and the like for reducing drug-resistant genome of intestinal flora|
    CN105795335A|2016-04-06|2016-07-27|秦家源|Clausena dentataRoem noodles and making method thereof|
    CN105768055B|2016-04-11|2020-01-24|中科和素（天津）医药科技有限公司|Nutritional preparation for conditioning intestinal tract and preparation method thereof|
    CN105747226A|2016-04-19|2016-07-13|洛阳咪谷食品有限公司|Method for preparing red-bean, coix-seed and almond wall-breaking nutrient food powder|
    CN105995420A|2016-05-19|2016-10-12|柳州市螺蛳粉协会|Spleen-strengthening stomach-nourishing nutritional rice noodles|
    CN105942511A|2016-05-26|2016-09-21|惠州同富康生物科技有限公司|Green-plum-contained health care food composition capable of regulating intestinal flora, and preparation method|
    CN106075130A|2016-07-15|2016-11-09|甘肃青黛百年健康管理股份有限公司|A kind of Health-protection traditional Chinese medicinal preparation for fat-eliminating slimming|
    CN106235329A|2016-07-29|2016-12-21|林少忠|A kind of functional food treating metabolic syndrome and preparation method thereof|
    CN106234900A|2016-08-17|2016-12-21|安徽詹氏食品股份有限公司|A kind of Chinese torreya vegetable protein beverage and preparation method thereof|
    CN106343358A|2016-08-26|2017-01-25|李时珍医药集团有限公司|Instant noodles with auxiliary gastric mucosa damage protection function|
    CN106262857A|2016-08-29|2017-01-04|林星海|A kind of nutraceutical and preparation method thereof|
    CN106509612A|2016-10-28|2017-03-22|完美（中国）有限公司|Usage of fiber composition for preparing foods for improving polycystic ovary syndrome|
    CN107536032A|2017-03-15|2018-01-05|无限极（中国）有限公司|A kind of Chinese medicine composition and its preparation method and application|
    CN106860853A|2017-04-10|2017-06-20|甘肃青黛百年健康管理股份有限公司|The diet-therapy health-preserving preparation of one class parting management fat|
    CN107198250B|2017-05-23|2019-03-12|北京瑞千景科技发展有限公司|Improve intestinal microecology Chronic disease prevention composition and balanced nutritious food and application|
    KR101952644B1|2017-09-21|2019-05-23|국가식품클러스터지원센터|The Inhibitory Obesity Effects of Amomum vilosum Loureiro Extracts and Composition Containing the Extract as Effective Ingredient|
    CN107712870A|2017-09-29|2018-02-23|王俊文|Nutritious food and preparation method thereof|
    CN108030084A|2017-11-30|2018-05-15|慈中华|Alimentation composition of kidney tonifying and preparation method thereof|
    CN108157814A|2017-12-25|2018-06-15|安徽生物肽产业研究院有限公司|The biological peptide vegetarian meal powder that intestines are led in a kind of nourishing the stomach, weight-reducing acts on|
    CN108094623A|2017-12-26|2018-06-01|潘信华|Honeysuckle tea electuary and preparation method thereof|
    CN108185100A|2018-01-30|2018-06-22|江西省农业科学院|One cultivates peanut oatmeal sugar and preparation method thereof|
    CN108719994A|2018-06-08|2018-11-02|包磊|A kind of fine willow generation meal Gly-His-Lys of the jade of nourishing the stomach weight reducing|
    CN108835467A|2018-06-20|2018-11-20|罗国球|A kind of preparation method of the red fruit nutrient solution with anti-cancer function|
    CN108813593A|2018-06-29|2018-11-16|湖南图强科技开发有限公司|A kind of thermostatic type health care product tanning machine|
    CN108783469A|2018-07-12|2018-11-13|王召利|A kind of vegetable active Gly-His-Lys and preparation method thereof adjusting intestinal flora|
    FR3083699B1|2018-07-13|2021-02-12|Laboratoires Arkopharma|EXCIPIENT IN SOLID FORM COMPRISING A SET OF NON CHEMICALLY MODIFIED VEGETABLE FOOD FIBERS|
    JP6765090B2|2019-05-14|2020-10-07|株式会社東洋新薬|Black ginger-containing composition|
    CN110140953A|2019-06-12|2019-08-20|上海紫微健康管理有限责任公司|Alimentation composition of metabolic syndrome symptom and preparation method thereof, purposes can be improved|
    CN110179108A|2019-07-01|2019-08-30|上海紫微健康管理有限责任公司|Alimentation composition of adjustable intestinal microflora and preparation method thereof, purposes|
    CN110583830A|2019-10-14|2019-12-20|焦建军|Tonka bean and lotus seed spleen-tonifying heart-calming substitutional tea|
    TWI719740B|2019-12-04|2021-02-21|大江生醫股份有限公司|Method for preparing plant fermentation product, and uses of the fermentation product and its active ingredients|
    法律状态:
    2018-05-02| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2019-09-03| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
    2020-06-16| B15K| Others concerning applications: alteration of classification|Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A23L 1/29 , A23L 1/09 Ipc: A23J 1/12 (2006.01), A23J 1/14 (2006.01) |
    2020-06-16| B07A| Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]|
    2020-10-13| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|
    2021-02-17| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2021-03-16| B09W| Correction of the decision to grant [chapter 9.1.4 patent gazette]|Free format text: RETIFICA-SE A PUBLICACAO DO PARECER DE DEFERIMENTO DA RPI 2615 DE 17/02/2021 POR TER SIDO EFETUADO COM INCORRECOES. |
    2021-04-06| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/11/2013, OBSERVADAS AS CONDICOES LEGAIS. |
    2021-05-18| B16C| Correction of notification of the grant [chapter 16.3 patent gazette]|Free format text: REF. RPI 2622 DE 06/04/2021 QUANTO AO ENDERECO. |
    优先权:
    申请号 | 申请日 | 专利标题
    CN201210489456.XA|CN102987383B|2012-11-27|2012-11-27|Balance intestinal Bacterial community improves complete nutritional composition and the application of metabolic syndrome|
    CN201210489456.X|2012-11-27|
    PCT/CN2013/087813|WO2014082560A1|2012-11-27|2013-11-26|Compositions for balancing gut microbiota and the preparation and the uses thereof|
    [返回顶部]